Celcuity Inc. (CELC) earnings date
Mar 24, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 21 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | after close | 44 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | after close | 44 | 8-K |
| Q4 FY2025 | Wed, Mar 25, 2026 | after close | 84 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | after close | 43 | 8-K |
| Q2 FY2025 | Thu, Aug 14, 2025 | after close | 45 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | after close | 44 | 8-K |
| Q4 FY2024 | Mon, Mar 31, 2025 | after close | 90 | 8-K |
What they guided beta
| Q3 FY2026 | "The randomized Phase 2 study to evaluate the efficacy and safety of, and determine the recommended Phase 3 dose level of, gedatolisib in combination with darolutamide in patients with prostate cancer is expected to begin in the first half of 2027." exhibit |
| Q3 FY2026 | "We expect that our current cash, cash equivalents and short-term investments will finance our operations through 2029." exhibit |
| Q2 FY2026 | "“We are on track to begin shipping REVTORPYK late in the third quarter of 2026, and we look forward to making this important therapy available to patients with locally advanced or metastatic breast cancer.”" exhibit |
| Q2 FY2026 | "Shipments of REVTORPYK are expected to begin late in the third quarter of 2026." exhibit |
| Q2 FY2026 | "Celcuity expects to provide further updates to results from both the PIK3CA MT and WT cohorts of VIKTORIA-1 at medical conferences in the fourth quarter. 1 st Line Setting Celcuity continues to advance gedatolisib combined with palbociclib and endocrine therapy in the first-line setting for patients with HR+/HER2- ABC through its ongoing Phase 3 VIKTORIA-2 clinical trial." exhibit |
| Q2 FY2026 | "The company expects to provide updated clinical data and additional visibility into its mCRPC development strategy during the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "We expect that our current cash, cash equivalents and short-term investments will finance our operations at least into 2029." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CELC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CELC
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CELC/"><img src="https://veritasdata.dev/embed/CELC.svg" alt="CELC earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CELC/)
Script
<script async src="https://veritasdata.dev/embed/CELC.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CELC"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.